[go: up one dir, main page]

WO2004067093A3 - Nk1 receptor antagonists for the treatment of functional dyspepsia - Google Patents

Nk1 receptor antagonists for the treatment of functional dyspepsia Download PDF

Info

Publication number
WO2004067093A3
WO2004067093A3 PCT/EP2004/000752 EP2004000752W WO2004067093A3 WO 2004067093 A3 WO2004067093 A3 WO 2004067093A3 EP 2004000752 W EP2004000752 W EP 2004000752W WO 2004067093 A3 WO2004067093 A3 WO 2004067093A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
receptor antagonists
functional dyspepsia
dyspepsia
functional
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2004/000752
Other languages
French (fr)
Other versions
WO2004067093A2 (en
Inventor
George Earl Dukes
Gareth Andrew Hicks
Gareth John Sanger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0301842A external-priority patent/GB0301842D0/en
Priority claimed from GB0301841A external-priority patent/GB0301841D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to EP04705094A priority Critical patent/EP1594574A2/en
Priority to JP2006501644A priority patent/JP2006516581A/en
Publication of WO2004067093A2 publication Critical patent/WO2004067093A2/en
Publication of WO2004067093A3 publication Critical patent/WO2004067093A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention relates to the use of NK1 receptor antagonists for the treatment of functional dyspepsia.
PCT/EP2004/000752 2003-01-27 2004-01-26 Nk1 receptor antagonists for the treatment of functional dyspepsia Ceased WO2004067093A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP04705094A EP1594574A2 (en) 2003-01-27 2004-01-26 Nk1 receptor antagonists for the treatment of functional dyspepsia
JP2006501644A JP2006516581A (en) 2003-01-27 2004-01-26 Use of chemical compounds to treat functional dyspepsia

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0301842.1 2003-01-27
GB0301842A GB0301842D0 (en) 2003-01-27 2003-01-27 Medicament
GB0301841.3 2003-01-27
GB0301841A GB0301841D0 (en) 2003-01-27 2003-01-27 Use of chemical compounds for the treatment of functional dyspepsia

Publications (2)

Publication Number Publication Date
WO2004067093A2 WO2004067093A2 (en) 2004-08-12
WO2004067093A3 true WO2004067093A3 (en) 2004-10-28

Family

ID=32827031

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/000752 Ceased WO2004067093A2 (en) 2003-01-27 2004-01-26 Nk1 receptor antagonists for the treatment of functional dyspepsia

Country Status (3)

Country Link
EP (1) EP1594574A2 (en)
JP (1) JP2006516581A (en)
WO (1) WO2004067093A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0403005D0 (en) * 2004-12-09 2004-12-09 Astrazeneca Ab New use
WO2014057003A1 (en) * 2012-10-11 2014-04-17 Nerre Therapeutics Limited Novel uses

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001025219A2 (en) * 1999-10-07 2001-04-12 Glaxo Group Limited Piperazine compounds
WO2002032867A1 (en) * 2000-10-17 2002-04-25 Glaxo Group Limited Chemical compounds
WO2003066635A1 (en) * 2002-02-08 2003-08-14 Glaxo Group Limited Piperidine derivatives

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001025219A2 (en) * 1999-10-07 2001-04-12 Glaxo Group Limited Piperazine compounds
WO2002032867A1 (en) * 2000-10-17 2002-04-25 Glaxo Group Limited Chemical compounds
WO2003066635A1 (en) * 2002-02-08 2003-08-14 Glaxo Group Limited Piperidine derivatives

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANDREWS PAUL L R ET AL: "Abdominal vagal afferent neurones: An important target for the treatment of gastrointestinal dysfunction.", CURRENT OPINION IN PHARMACOLOGY, vol. 2, no. 6, December 2002 (2002-12-01), pages 650 - 656, XP002279475, ISSN: 1471-4892 (ISSN print) *
STANGHELLINI VINCENZO ET AL: "New developments in the treatment of functional dyspepsia.", DRUGS, vol. 63, no. 9, 2003, pages 869 - 892, XP009030452, ISSN: 0012-6667 *

Also Published As

Publication number Publication date
WO2004067093A2 (en) 2004-08-12
EP1594574A2 (en) 2005-11-16
JP2006516581A (en) 2006-07-06

Similar Documents

Publication Publication Date Title
WO2007061763A3 (en) Indole orexin receptor antagonists
AP2004002982A0 (en) Urea-compounds active as vanilloid receptor antagonists for the treatment of pain.
WO2005040169A3 (en) Fused heterocyclic compounds as serotonin receptor modulators
WO2008008517A3 (en) Bridged diazepan orexin receptor antagonists
ZA200701656B (en) Humanized anti-cment antagonists
NO20034122D0 (en) Amalgamated pyridine derivatives for use as vanilloid receptor antagonists for the treatment of pain
ZA200408335B (en) Pyrrolidinium derivatives as antagonists of M3 muscarinic receptors.
WO2007126934A3 (en) Amidoethylthioether orexin receptor antagonists
ATE384050T1 (en) BENZAZEPINE DERIVATIVES AS HISTAMINE H3 ANTAGONISTS
MY161834A (en) Substituted diazepan compounds as orexin receptor antagonists
WO2003028641A3 (en) Mch receptor antagonists
WO2007126935A3 (en) Diazepan orexin receptor antagonists
WO2007076070A3 (en) Modulators of muscarinic receptors
WO2007025069A3 (en) Diazaspirodecane orexin receptor antagonists
WO2005030188A3 (en) Phenyl-piperazine derivatives as modulators of muscarinic receptors
NO20034311D0 (en) CCR5 antagonists for the treatment of AIDS
DK1440059T3 (en) 3-azabicyclo (3.1.0) hexane derivatives as opioid receptor antagonists
TWI348467B (en) Nk1 antagonists
WO2006023852A3 (en) Modulators of muscarinic receptors
WO2006058294A3 (en) Modulators of muscarinic receptors
PL1636221T3 (en) 3-Heterocyclyl-Azetidine compounds useful as NK1/NK2 receptors antagonists
WO2004091490A3 (en) Somatostatin-dopamine chimeric analogs
WO2005023302A3 (en) Anti-cd20 therapy of ocular disorders
DE602004014772D1 (en) PYRROL-2,5-DITHION DERIVATIVES AS MODULATORS OF THE LIVER-X RECEPTOR
AU2003290059A1 (en) Use of cd137 antagonists for the treatment of tumors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006501644

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2004705094

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004705094

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2004705094

Country of ref document: EP